Home/Pipeline/Baxdrostat

Baxdrostat

Resistant Hypertension

Phase IIIActiveN/A

Key Facts

Indication

Resistant Hypertension

Phase

Phase III

Status

Active

Company

AstraZeneca

About AstraZeneca

AstraZeneca is a global biopharmaceutical leader with a mission to push the boundaries of science to deliver life-changing medicines. The company has achieved significant commercial success with 16 blockbuster drugs and a robust pipeline of 197 projects, underpinned by a 'Growth Through Innovation' strategy focused on disease biology, next-generation therapeutics, predictive clinical success, and clinical innovation. AstraZeneca's strategic integration of data science, AI, and novel therapeutic modalities positions it to maintain its competitive edge and address complex healthcare challenges across its core therapeutic areas.

View full company profile

Therapeutic Areas

Oncology Cardiovascular/Renal/Metabolic Respiratory & Immunology Rare Disease Vaccines & Immune Therapies

Other Resistant Hypertension Drugs

Drug	Company	Phase	Status
Barostim™	CVRx	CE Mark	Deprioritized (U.S.)
Firibastat (QGC001)	Quantum Genomics	Phase 3	Terminated
DirectAblate Renal Denervation System	Symple Surgical	Pre-clinical	Active
Aprocitentan	Johnson & Johnson	Approved	Launch Phase
TRYVIO/JERAYGO (aprocitentan)	Idorsia	Marketed	Commercial